Section Arrow
BOLT.NASDAQ
- Bolt Biotherapeutics
Quotes are at least 15-min delayed:2024/05/16 10:27 EDT
Last
 0.8615
+0.0315 (+3.80%)
Day High 
0.87 
Prev. Close
0.83 
1-M High
1.335 
Volume 
173.93K 
Bid
0.861
Ask
0.862
Day Low
0.84745 
Open
0.86 
1-M Low
0.8288 
Market Cap 
31.65M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.14 
20-SMA 1.13 
50-SMA 1.2 
52-W High 2.03 
52-W Low 0.8288 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.83/-1.72
Enterprise Value
49.08M
Balance Sheet
Book Value Per Share
2.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
5.73M
Operating Revenue Per Share
0.18
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.2776+0.0225+8.82%-- 
SCPXScorpius Holdings0.0951+0.0174+22.39%-- 
DNAGinkgo Bioworks Holdings0.8113-0.0278-3.31%-- 
NVAXNovavax12.9922+0.0922+0.71%-- 
NBYNovaBay Pharmaceuticals0.0965-0.008-7.66%-- 
Quotes are at least 15-min delayed:2024/05/16 10:27 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.